DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?]

Author(s): Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M

Affiliation(s): Klinik und Poliklinik fur Neurologie der Universitat Essen Hufelandstr. 55 45122 Essen, Germany. h.diener@uni-essen.de

Publication date & source: 2001-05, Z Kardiol., 90(5):348-51.

Publication type: Clinical Trial; Randomized Controlled Trial

In a post hoc analysis of the European Stroke Prevention Study 2 (ESPS2), we investigated whether dipyridamole given as antiplatelet drug in patients with TIA or stroke increases the risk of cardiac events. ESPS2 was a secondary prevention trial including 6602 patients with TIA or stroke. Patients were randomized into one of four treatment arms: 2 x 25 mg acetylsalicylic acid (ASA), 2 x 200 mg slow release dipyridamole (DP), the combination of DP and ASA and placebo. DP did not result in a higher number of cardiac events, e.g., angina pectoris, myocardial infarction or death. The combination of ASA plus DP was superior to either drug alone in the prevention of strokes.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017